/ 2 items

#CCCC↓

Featured/ CCCC/ 05/29/2026 · 1:22 PM

C4 Therapeutics Shares Rocket as Bristol Myers Squibb’s Mezigdomide Phase 3 Triumph Lights Up Protein Degrader Sector

C4 Therapeutics stock jumped after Bristol Myers Squibb announced strong Phase 3 SUCCESSOR-2 results for mezigdomide in multiple myeloma.

CCCC/ 12/02/2025 · 5:59 AM

TD Cowen Starts Coverage on C4 Therapeutics with a Buy Rating

TD Cowen initiates C4 Therapeutics with a Buy rating, highlighting its strong clinical validation in targeted protein degradation and the potential of Cemsi as a "backbone therapy" for multiple myeloma.